CA2377246A1 - Derives d'arylthiazolidinedione et d'aryloxazolidinedione - Google Patents
Derives d'arylthiazolidinedione et d'aryloxazolidinedione Download PDFInfo
- Publication number
- CA2377246A1 CA2377246A1 CA002377246A CA2377246A CA2377246A1 CA 2377246 A1 CA2377246 A1 CA 2377246A1 CA 002377246 A CA002377246 A CA 002377246A CA 2377246 A CA2377246 A CA 2377246A CA 2377246 A1 CA2377246 A1 CA 2377246A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- aryl
- independently selected
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des 5-aryle-2,4-thiazolidinediones et oxazolidinediones substituées, qui sont des agonistes puissants vis-à-vis du PPAR, et qui sont donc utiles pour le traitement, le contrôle et la prévention des affections suivantes : diabète, hyperglycémie, hyperlipidémie (y compris l'hypercholestérolémie et l'hypertriglycéridémie), athérosclérose, obésité, resténose vasculaire et autres maladies, troubles ou états dont la médiation est assurée par le PPAR .alpha. et/ou .gamma..
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13992999P | 1999-06-18 | 1999-06-18 | |
US60/139,929 | 1999-06-18 | ||
PCT/US2000/016769 WO2000078313A1 (fr) | 1999-06-18 | 2000-06-16 | Derives d'arylthiazolidinedione et d'aryloxazolidinedione |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2377246A1 true CA2377246A1 (fr) | 2000-12-28 |
Family
ID=22488938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002377246A Abandoned CA2377246A1 (fr) | 1999-06-18 | 2000-06-16 | Derives d'arylthiazolidinedione et d'aryloxazolidinedione |
Country Status (8)
Country | Link |
---|---|
US (2) | US6380191B1 (fr) |
EP (1) | EP1194147B1 (fr) |
JP (1) | JP2003502370A (fr) |
AU (1) | AU770870B2 (fr) |
CA (1) | CA2377246A1 (fr) |
DE (1) | DE60032898T2 (fr) |
ES (1) | ES2277842T3 (fr) |
WO (1) | WO2000078313A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5876900A (en) * | 1999-06-18 | 2001-01-09 | Merck & Co., Inc. | Process for making arylthiazolidinedione derivatives |
US6613519B1 (en) * | 2000-04-20 | 2003-09-02 | Rappaport Family Institute For Reseach In The Medical Sciences | Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease |
EP1911462A3 (fr) | 2001-01-26 | 2011-11-30 | Schering Corporation | Combinaisons comprenant un inhibiteur d'absorption de stérol |
CA2561230A1 (fr) | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones en tant que modulateurs des ppar delta et leur utilisation |
WO2005097762A2 (fr) | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee |
US20090118337A1 (en) * | 2005-06-03 | 2009-05-07 | Davis Pamela B | Methods and compositions for treating inflammation |
CA2624102A1 (fr) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques |
KR20080048520A (ko) * | 2005-09-29 | 2008-06-02 | 사노피-아벤티스 | 페닐 그룹을 갖는, 페닐- 및 피리딜-1,2,4-옥사디아졸론유도체, 이의 제조 방법 및 약제로서의 이의 용도 |
US9308198B2 (en) | 2006-09-08 | 2016-04-12 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
US8160503B2 (en) * | 2009-02-27 | 2012-04-17 | Research In Motion Limited | Method and system for characterizing a radio channel of a wireless network using variability of synchronization |
WO2010114896A1 (fr) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Composés indolo-pyridinone substitués |
WO2012027331A1 (fr) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
US4200642A (en) | 1978-08-21 | 1980-04-29 | Pfizer Inc. | Spiro-oxazolidindiones |
US4342771A (en) | 1981-01-02 | 1982-08-03 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4332952A (en) | 1980-07-28 | 1982-06-01 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4367234A (en) | 1980-07-28 | 1983-01-04 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4689336A (en) | 1981-01-02 | 1987-08-25 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine 2,4-diones |
US4695634A (en) | 1981-01-02 | 1987-09-22 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4423233A (en) | 1981-04-23 | 1983-12-27 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4430337A (en) | 1982-06-23 | 1984-02-07 | Pfizer Inc. | Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity |
DE3856378T2 (de) * | 1987-09-04 | 2000-05-11 | Beecham Group Plc | Substituierte Thiazolidindionderivate |
GB8820389D0 (en) * | 1988-08-26 | 1988-09-28 | Beecham Group Plc | Novel compounds |
US5053420A (en) | 1989-10-13 | 1991-10-01 | Pershadsingh Harrihar A | Thiazolidine derivatives for the treatment of hypertension |
GB9017218D0 (en) | 1990-08-06 | 1990-09-19 | Beecham Group Plc | Novel compounds |
JP3053490B2 (ja) | 1991-02-25 | 2000-06-19 | 杏林製薬株式会社 | チアゾリジン−2,4−ジオン誘導体とその塩及び製造法 |
US5498621A (en) | 1992-05-01 | 1996-03-12 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
TW268952B (fr) | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
US5614544A (en) | 1993-09-14 | 1997-03-25 | Takeda Chemical Industries, Ltd. | Oxazolidinedione derivatives and their use |
NO305987B1 (no) * | 1994-04-11 | 1999-08-30 | Sankyo Co | Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse |
US5594015A (en) | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
TW403748B (en) | 1994-11-02 | 2000-09-01 | Takeda Chemical Industries Ltd | An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same |
TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
JPH0912575A (ja) | 1995-06-28 | 1997-01-14 | Sankyo Co Ltd | ベンゾオキサジンおよびベンゾチアジン誘導体 |
JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
ATE262334T1 (de) | 1996-02-02 | 2004-04-15 | Merck & Co Inc | Antidiabetisches mittel |
ES2202582T3 (es) | 1996-02-02 | 2004-04-01 | MERCK & CO., INC. | Agentes antidiabeticos. |
AU708055B2 (en) | 1996-02-02 | 1999-07-29 | Merck & Co., Inc. | Heterocyclic derivatives as antidiabetic and antiobesity agents |
ATE293963T1 (de) | 1996-02-02 | 2005-05-15 | Merck & Co Inc | Verfahren zur behandlung von diabetes und verwandter krankheitszustände. |
WO1997028149A1 (fr) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Procede pour augmenter les niveaux de cholesterol hdl |
US5801173A (en) | 1996-05-06 | 1998-09-01 | Dr. Reddy's Research Foundation | Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
US6008237A (en) * | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
-
2000
- 2000-06-16 JP JP2001504376A patent/JP2003502370A/ja not_active Withdrawn
- 2000-06-16 CA CA002377246A patent/CA2377246A1/fr not_active Abandoned
- 2000-06-16 DE DE60032898T patent/DE60032898T2/de not_active Expired - Fee Related
- 2000-06-16 ES ES00942916T patent/ES2277842T3/es not_active Expired - Lifetime
- 2000-06-16 AU AU57468/00A patent/AU770870B2/en not_active Ceased
- 2000-06-16 US US09/595,840 patent/US6380191B1/en not_active Expired - Fee Related
- 2000-06-16 WO PCT/US2000/016769 patent/WO2000078313A1/fr active IP Right Grant
- 2000-06-16 EP EP00942916A patent/EP1194147B1/fr not_active Expired - Lifetime
-
2001
- 2001-11-21 US US09/990,470 patent/US6465497B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1194147B1 (fr) | 2007-01-10 |
WO2000078313A1 (fr) | 2000-12-28 |
DE60032898T2 (de) | 2007-10-25 |
EP1194147A4 (fr) | 2002-10-09 |
US20020037911A1 (en) | 2002-03-28 |
AU770870B2 (en) | 2004-03-04 |
EP1194147A1 (fr) | 2002-04-10 |
ES2277842T3 (es) | 2007-08-01 |
US6465497B2 (en) | 2002-10-15 |
JP2003502370A (ja) | 2003-01-21 |
AU5746800A (en) | 2001-01-09 |
US6380191B1 (en) | 2002-04-30 |
DE60032898D1 (de) | 2007-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6399640B1 (en) | Arylthiazolidinedione and aryloxazolidinedione derivatives | |
US6200998B1 (en) | Arylthiazolidinedione derivitives | |
AU740733B2 (en) | Arylthiazolidinedione derivatives | |
US6569879B2 (en) | Aryloxyacetic acids for diabetes and lipid disorders | |
US20020042441A1 (en) | N-substituted indoles useful in the treatment of diabetes | |
CA2400021A1 (fr) | Acides aryloxyacetiques utilises en cas de diabete et de troubles lipidiques | |
US20020082292A1 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
US6465497B2 (en) | Arylthiazolidinedione derivatives | |
MXPA06008190A (es) | Oxazolidindionas y tiazolidindionas antidiabeticas. | |
US20090069385A1 (en) | Antidiabetic Oxazolidinediones and Thiazolidinediones | |
MXPA00006035A (en) | Arylthiazolidinedione derivatives | |
CZ20002286A3 (cs) | Arylthiazolidindionové deriváty |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |